Compass Therapeutics: When Your Lead Asset's Timeline Becomes the Entire Investment Thesis

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

CMPX typically reports earnings before market open, meaning Day 0 captures the first trading session reaction while Day +1 reflects follow-through momentum.

Historical price behavior shows significant volatility around earnings releases, with an average absolute Day 0 move of 5.01% and Day +1 move of 3.62%. The most dramatic reaction came in August 2025 when the stock surged +23.70% on Day 0, though it gave back some gains the following session. More recently, the May 2026 report produced relatively muted movement with just a 0.52% Day 0 gain followed by a 4.10% Day 1 decline.

The 10.37% average Day 0 range indicates substantial intraday volatility regardless of direction, suggesting active trading and position adjustments as investors digest results. The 8.30% average Day 1 range shows continued volatility into the follow-through session. Investors should prepare for potentially sharp moves in either direction, with recent history showing the stock can swing dramatically based on pipeline updates and cash burn commentary rather than just the EPS figure itself.

Part 2.2: Options Market Expected Move

The options market is pricing a 14.66% expected move through the August 21 expiration, which is substantially higher than the 5.01% average historical Day 0 move but more in line with the 10.37% average intraday range. This elevated implied volatility of 154.50% suggests options traders are anticipating a larger-than-typical reaction, possibly reflecting uncertainty around pipeline updates or cash position disclosures that could accompany the earnings release.

Part 3: What Analysts Are Saying

Analysts maintain strong conviction on Compass Therapeutics despite the company's pre-revenue status and recent earnings miss. The consensus shows 15 Strong Buy ratings, 0 Moderate Buys, 2 Holds, and no Sell ratings among 17 analysts covering the stock. This translates to an average recommendation of 4.76 out of 5.0, reflecting overwhelmingly bullish sentiment.

The average price target of $8.50 implies 295% upside from the current price of $2.15, with estimates ranging from a low of $4.00 (86% upside) to a high of $24.00 (1,016% upside). This wide range reflects the binary nature of clinical-stage biotech investing, where outcomes depend heavily on trial results and regulatory decisions.

Sentiment has remained unchanged over the past month according to the trend indicator, suggesting analysts are maintaining their bullish stance despite the recent earnings disappointment. The consistency of the Strong Buy consensus indicates analysts view current weakness as a buying opportunity rather than a reason to downgrade, likely based on confidence in the pipeline's long-term potential rather than near-term financial performance.

Part 4: Technical Picture

The technical setup heading into earnings is decidedly bearish, with the Barchart Technical Opinion showing a 72% Sell signal. While this represents an improvement from last week's 88% Sell reading, it marks a significant deterioration from last month's 40% Sell, indicating mounting technical pressure over the intermediate term.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains negative despite recent stabilization
• Medium-term (50% Sell): Moderate sell signal suggests continued weakness in the intermediate timeframe with no clear reversal pattern
• Long-term (100% Sell): Strong sell signal reflects significant deterioration in the longer-term trend structure

Trend Characteristics: The trend is rated as "Good" strength but in the "Weakest" direction, indicating a well-defined downtrend with consistent selling pressure.

The stock is trading at $2.15, positioned above its 5-day ($1.98), 10-day ($1.98), 20-day ($2.04), and 50-day ($2.10) moving averages, suggesting a short-term bounce within a larger downtrend. However, the price remains well below the 100-day ($2.98) and 200-day ($4.16) moving averages, confirming the longer-term bearish structure. The stock has lost nearly 48% from its 200-day average, reflecting sustained selling pressure over the past several months.

Key resistance now sits at the 50-day moving average of $2.10, which the stock has just barely cleared. More significant overhead resistance lies at the 100-day average near $2.98, representing a 39% move from current levels. The overall technical setup is cautionary heading into earnings, with the stock attempting to stabilize after a prolonged decline but lacking any meaningful bullish momentum. The combination of strong sell signals across all timeframes and the wide gap to longer-term averages suggests limited technical support if the earnings report disappoints. Conversely, a positive surprise could trigger a sharp short-covering rally given the oversold conditions and bearish positioning.